Science of Coagulation

Blood coagulation is an important part of the host defense mechanism required for repair and maintenance of the circulatory system. This complex and multifactorial process has been described to contain two parallel but distinct pathways; hemostasis and thrombosis.

Learn More About Our Science

Why Factor XIa?

Factor XIa is a clinically-validated target for the prevention of thrombosis by selectively inhibiting the activation of the intrinsic (contact) pathway, without impacting normal hemostasis (bleeding) through the extrinsic pathway.

Learn More About Factor XIa

About EP-7041

  • eXIthera’s lead IV candidate EP-7041 is a novel, potent and selective small-molecule Factor XIa inhibitor
  • Completed Phase 1 demonstrating safety, tolerability and ideal clinical PK profile with validated efficacy marker aPTT
  • Established that effective anticoagulation is achievable with a small molecule therapeutic without the danger of increased bleeding risk or the need for a reversal agent
  • Preventing major bleeding events saves lives and will significantly reduce healthcare costs

News

EP-7041 is a novel, potent, selective small molecule FXIa inhibitor designed to prevent thrombosis with limited risk for bleeding side effects. Results from the Phase 1a/1b study were highlighted in a poster presentation on Nov. 13 at the American Heart Association (AHA) Scientific Sessions 2017, in Anaheim, California.
eXIthera Pharmaceuticals Inc. CEO Neil Hayward told BioWorld he's hoping to build a "continuum of care" around factor XIa inhibitor EP-7041, after Phase I data showed the intravenous (I.V.) version of the antithrombotic safe and well-tolerated in healthy volunteers after single or multiple ascending intravenous doses – and even turned up some clues to efficacy.